CDC/ACIP [to 28 May 2016]

CDC/ACIP [to 28 May 2016]

THURSDAY, MAY 26, 2016
CDC adds Argentina to interim travel guidance related to Zika virus
Today, CDC posted a Zika virus travel notice for Argentina. Local transmission of Zika virus infection (Zika) has been reported in Tucumán Province, Argentina.

THURSDAY, MAY 26, 2016
CDC Director Addresses National Press Club
CDC Director Tom Frieden, M.D., M.P.H., discussed the latest news and developments in the Zika virus outbreak today at the National Press Club.

MMWR May 27, 2016 / Vol. 65 / No. 20
:: Possible Zika Virus Infection Among Pregnant Women — United States and Territories, May 2016
:: Notes from the Field: Outbreak of Serogroup B Meningococcal Disease at a University — California, 2016
:: Notes from the Field: Expanded Chemoprophylaxis Offered in Response to a Case of Meningococcal Meningitis in an Elementary School — Indiana, 2015
:: Notice to Readers: Changes in the Presentation of Zika Virus Disease, Non-Congenital Infection, and Addition of Zika Virus Congenital Infection to Notifiable Diseases and Mortality Table I

June ACIP meeting
June 22-23, 2016
Deadline for registration:
:: Non-US Citizens: May 20, 2016
:: US Citizens: June 6, 2016
Registration is NOT required to watch the live meeting webcast or to listen via telephone.
Draft June 22-23, 2016 Meeting Agenda[2 pages]

IOM, Partners Launch Vaccination Campaigns to Combat Measles in South Sudan

IOM, Partners Launch Vaccination Campaigns to Combat Measles in South Sudan
South Sudan – In response to an increase of measles cases, IOM South Sudan is teaming up with health agencies to vaccinate vulnerable people against the disease. IOM recently led vaccination campaigns for internally displaced persons (IDPs) in Bentiu and Malakal and additional campaigns are in progress.

Following several suspected cases of measles in the UN Protection of Civilians (PoC) sites in Bentiu and Malakal, IOM launched a vaccination campaign for children under five living in both sites. The campaigns vaccinated nearly 45,900 children in Bentiu and 7,300 children in Malakal, reaching over 90 percent of the target group.

The campaigns were implemented in collaboration with International Medical Corps, International Rescue Committee, Médecins Sans Frontières, UNICEF, WHO and World Relief. Led by IMC, the Malakal campaign was also expanded to Malakal town, vaccinating 919 children against the disease.

“The success of these campaigns is due to intensive social mobilization, effective collaboration and leadership of the Health Cluster. But routine immunizations should be strengthened both within and outside of PoC sites to reduce the likelihood of further measles cases, especially among children,” said IOM Migration Health Emergency Coordinator Dr. Andrew Mbala.

Measles is a highly contagious disease that can become life threatening if complications, such as pneumonia, arise. Children and displaced populations living in crowded areas are particularly vulnerable to outbreaks of measles and other contagious diseases.
An IOM Health Rapid Response Team is currently on the ground in Yirol East and West counties to provide measles vaccines for another 46,900 children under five. Health actors have reported 31 suspected measles cases in the two counties this year.

At IOM’s primary health care clinics in Bentiu and Malakal, as well as in Renk, IOM clinics are providing regular vaccinations against common diseases, such as tuberculosis, cholera and polio. Last week, IOM vaccinated 575 children through routine vaccinations.
To date in 2016, 1,321 suspected measles cases have been reported by the Health Cluster and South Sudan Ministry of Health.

Gavi [to 28 May 2016]

Gavi [to 28 May 2016]

26 May 2016
Gavi welcomes price trend for pentavalent vaccine
Latest price information published by UNICEF.
Geneva, 26 May 2016 – Gavi, the Vaccine Alliance welcomes the continued trend of decreasing prices for five-in-one pentavalent vaccine. Prices for pentavalent doses to be supplied to Gavi-supported countries over the next two years have been published by UNICEF following the completion of the first stage of a multi-stage tender.

The pentavalent vaccine protects against five major infections in one shot: diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type b (Hib). It remains a cornerstone of Gavi’s immunisation efforts and is the first vaccine to have been introduced into the routine immunisation systems of all Gavi-supported countries…


23 May 2016
World Humanitarian Summit – Gavi’s Fragility and Immunisation Policy
Gavi to review its response to humanitarian emergencies and fragile settings in 2016.
Geneva, 23 May 2016 – Gavi, the Vaccine Alliance remains committed to working in fragile settings and has increased its focus on the specific challenges they pose through its current Fragility and Immunisation policy.

Approved in 2012, the policy paths the way for flexible and country tailored approaches, in which approximately one third of Gavi funding is invested (nearly US$ 425 million in 2015). Under the terms of this policy, Gavi will continue to provide vaccines to governments for refugees and internally displaced populations in Gavi-supported countries.

In 2016, Gavi has committed to reviewing its response to humanitarian emergencies and fragile settings to ensure that the Alliance’s response is in line with best practices in such environments.

Under Gavi’s 2016-2020 strategy, the Vaccine Alliance has committed to reaching the un-reached with life-saving vaccines and investing in building resilient health systems. This includes investment in national laboratory and surveillance capacity strengthening in line with the core capacities of the international health regulations.

Recognising that outbreaks can create urgent needs with humanitarian consequences, existing efforts such as funding vaccine stockpiles for outbreak response will also continue to be enhanced. For example, Gavi has committed to purchasing the first generation Ebola vaccine for a global stockpile once a vaccine(s) is licensed and WHO recommended.

Gavi will remain committed to innovative engagement with partners and countries to help prepare, detect and respond to disease outbreaks and thereby help protect the health of millions of people including in fragile environments.

Global Fund [to 28 May 2016]

Global Fund [to 28 May 2016]

25 May 2016 to Bring Better Access, Prices, Transparency to Global Health
GENEVA – The Global Fund to Fight AIDS, Tuberculosis and Malaria and the Government of Canada announced a new online marketplace today that is projected to save at least US$250 million in the coming four years by offering health implementers competitive prices for medicines and health commodities.

Simple and accessible, provides up-to-date information on available products, prices, expected delivery time and tracking. Buyers and suppliers can use it as a safe and reliable tool for procuring quality-assured goods in less time and with lower financial risk. also allows orders to be pooled, enabling even smaller buyers to achieve economies of scale for substantial savings. With an easy-to-use platform, it is set up to be an effective procurement tool for governments and civil society organizations that implement health grants, significantly supporting the common goal of building resilient and sustainable systems for health.

“Canada is taking concrete action to end for good three of the world’s most devastating diseases – AIDS, tuberculosis, and malaria – by 2030,” said Marie-Claude Bibeau, Canada’s Minister of International Development and La Francophonie. “By investing in, Canada is leveraging technology to simplify procurement and create significant savings. This innovative platform allows countries to improve efficiency and deliver medicines and health products that will save lives.”

The Government of Canada is contributing CAD19 million (US$14.5 million) to help build and expand Canada, a leader in many aspects of global health, is also hosting the Global Fund’s Fifth Replenishment in Montreal in September 2016. UNITAID and the Clinton Health Access Initiative (CHAI) are also strategic partners in supporting the development of…

PATH [to 28 May 2016]

PATH [to 28 May 2016]
Press release | May 26, 2016
Kakamega civil society leaders launch new alliance to improve health for women, newborns, and children
Kakamega, Kenya, May 27, 2016 – Today, twenty local civil society organizations dedicated to improving health and well-being in Kakamega County launched a new alliance to advocate for strengthened county policies and increased investment in maternal, newborn, and child health (MNCH).

Even with progress, Kakamega County has among the highest rates of maternal and child deaths in Kenya…

PATH, an international nonprofit organization that has worked in partnership with local organizations and county governments in Kenya for more than a decade, helped to bring together the alliance. Comprised of community-based organizations with a strong presence in Kakamega County, the alliance will advocate for stronger MNCH policies at the county level…

European Medicines Agency [to 28 May 2016]

European Medicines Agency [to 28 May 2016]

Two new combination therapies against chronic hepatitis C
Direct-acting antivirals Epclusa and Zepatier recommended for approval
The European Medicines Agency (EMA) has recommended the granting of marketing authorisations in the European Union (EU) for two new combination therapies against chronic (long-term) hepatitis C virus (HCV) infection, Epclusa (sofosbuvir/velpatasvir) and Zepatier (grazoprevir/elbasvir).

HCV infection is a major European public health challenge. It affects between 0.4% and 3.5% of the population in different EU Member States and is the most common single cause of liver transplantation in the region.

Epclusa and Zepatier belong to a new generation of medicines for chronic HCV infection, direct-acting antivirals, that give high rates of cure of HCV infection and that have, in the past few years, reshaped the way this disease is treated. These medicines block the action of proteins which are essential for viral replication. Epclusa targets the proteins NS5B and NS5A, while Zepatier targets the proteins NS3/4A and NS5A…


Improving safety of first-in-human clinical trials
EMA starts EU-wide reflection on necessary changes to best practices
The European Medicines Agency (EMA) has started a review of the guidelines that describe first-in-human clinical trials and the data needed to enable their appropriate design and allow initiation. This is being done in cooperation with the European Commission and the Member States of the European Union (EU).

The review will identify which areas may need to be revised in the light of the tragic incident which took place during a Phase I first-in-human clincial trial in Rennes, France, in January 2016. The trial led to the death of one participant and hospitalisation of five others…

AERAS [to 28 May 2016]

AERAS [to 28 May 2016]

May 23, 2016
Aeras Applauds Report and Recommendations by the Review on Antimicrobial Resistance
Aeras Applauds the Final Report and Recommendations by the United Kingdom Review on Antimicrobial Resistance

Rockville, MD,– Aeras applauds the Final Report and Recommendations released this week by the U.K. Review on Antimicrobial Resistance (Review) that highlights the extreme global health threat of antimicrobial resistance (AMR). The Review, led by economist Jim O’Neill, specifically notes the threat of multidrug-resistant tuberculosis (MDR-TB) and the imperative of increased global investment in research and development to save the millions of lives lost each year due to AMR related to tuberculosis (TB) and other infectious diseases.

The final report warns that if new therapies, diagnostics and a new vaccine are not introduced, MDR-TB will be responsible for 2.5 million deaths per year by 2050, or roughly one quarter of the forecasted 10 million deaths related to AMR – equating to one death due to MDR-TB every 12 seconds. An interim paper entitled Vaccines and Alternative Approaches: Reducing our Dependence on Antimicobials, published by the Review in February 2016, also emphasized the overwhelming need for new TB vaccines as an essential component of the global strategy to overcome TB and to address MDR-TB.

A key finding of the final report is that increased public and private investment in research and development will be essential to combatting AMR – saving millions of lives, as well as avoiding the serious economic impact of this global public health emergency…